JNJ-90301900

Phase 3Small molecule

JJohnson & Johnson Enterprise Innovation Inc.

JNJ-90301900 is one of 119 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Carcinoma, Non-Small-Cell LungRecruiting

Carcinoma, Squamous CellRecruiting

Squamous Cell Carcinoma of Head and NeckRecruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 1

Active, not recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Recruiting

Carcinoma, Squamous CellPhase 3

Recruiting

Squamous Cell Carcinoma of Head and NeckPhase 1

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

JNJ-90301900

JJohnson & Johnson Enterprise Innovation Inc.

Phase 3

3 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

Vidaza

Bristol-Myers Squibb

Preclinical

1 10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Carcinoma, Squamous Cell

NCT04892173

Q3 2028

Phase 1Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07219212

Q4 2028

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667908

Clinical

Trials by Indication[1]

Carcinoma, Squamous Cell1 trial

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma

Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 3·NCT04892173·500 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 2·NCT06667908·130 enrolled

Squamous Cell Carcinoma of Head and Neck1 trial

A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 1·NCT07219212·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for JNJ-90301900. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-90301900 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-90301900. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Enterprise Innovation Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJohnson & Johnson Enterprise Innovation Inc.

JNJ-90301900

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q4 2028

Trials by Indication[1]

Carcinoma, Squamous Cell1 trial

Carcinoma, Non-Small-Cell Lung1 trial

Squamous Cell Carcinoma of Head and Neck1 trial

References

Drug Info

Quick Facts

Related News